Imatinib mesylate, a targeted medication used to treat specific forms of cancer, is present in imatib tablets. Imatinib is typically administered to treat gastrointestinal stromal tumours (GIST) and chronic myeloid leukaemia (CML). It belongs to the group of drugs known as tyrosine kinase inhibitors, which stop the action of particular enzymes that help cancer develop. Imatib efficiently inhibits the proliferation of cancer cells with aberrant tyrosine kinase activity and causes cell death. The oral tablets are typically taken every day. Imatib has benefits, but it also has risks, such as haematological abnormalities, edoema, musculoskeletal pain, and nausea. Throughout treatment, regular monitoring by medical specialists is crucial.
Available under the brand name of Cipla, Tablets have wide applications in health clinics and hospitals. Accessible in 400 mg quantity in 1x 10 packaging size, these tablets need to be taken after consulting with a medical practitioner.